Lipid clinic experience with bempedoic acid in three UK centres

• Published in: Current medical research and opinion 2024-06, Vol.40 (6), p.911-916
• Main Authors: Jakubowska, Agnieszka, Al Hasani, Wiaam, Williams, Jamal, MacMahon, Zofia, Balbas, Bryan, Crook, Martin A., Viljoen, Adie, Reynolds, Timothy M., Wierzbicki, Anthony S.
• Format: Article
• Language: English
• ISSN: 0300-7995; 1473-4877
• DOI: 10.1080/03007995.2024.2341870

OBJECTIVENovel lipid-lowering therapies are being introduced. Few studies exist of the real-world effectiveness of adenosine-tri-phosphate citrate lyase inhibition with bempedoic acid.METHODSThis study audited bempedoic acid therapy in 216 consecutive patients from three hospital centres - a university hospital (n = 77) and two district general hospitals (n = 106 and 33). Cardiovascular disease (CVD) risk factors, prescription qualification criteria, efficacy and adverse effects were assessed.RESULTSThe population was aged 65.9 ± 11.0 years, 42% were male, 25% had type 2 diabetes, and 31% had familial hypercholesterolaemia. CVD was present in 19% and multibed vascular disease in 8%. Statin intolerance was reported in 92%. Bempedoic acid reduced total cholesterol by 1.58 ± 1.44 mmol/L (20%), LDL-C by 1.37 ± 1.31 mmol/L (27%), triglycerides by 0.22 mmol/L (2%) with an 0.06 mmol/L (1%) increase in HDL-C after 22 ± 9 months follow-up. An LDL-C